» Articles » PMID: 8717505

Altered Peptide Ligand-induced Partial T Cell Activation: Molecular Mechanisms and Role in T Cell Biology

Overview
Date 1996 Jan 1
PMID 8717505
Citations 195
Authors
Affiliations
Soon will be listed here.
Abstract

The elucidation of the phenomena of T cell antagonism and partial activation by altered peptide ligands has necessitated a revision in the traditional concepts of TCR recognition of antigen and subsequent signal transduction. Whereas previous models supported a single ligand specificity for any particular T cell, many studies using analogs of immunogenic peptides have now demonstrated a flexibility in this recognition. Moreover, interaction with such altered peptide ligands can result in dramatically different phenotypes of the T cells, ranging from inducing selective stimulatory functions to completely turning off their functional capacity. Investigations of the biochemical basis leading to these phenotypes have shown that altered peptide ligands can induce a qualitatively different pattern of signal transduction events than does any concentration of the native ligand. Such observations imply that several signaling modules are directly linked to the TCR/CD3 complex and that they can be dissociated from each other as a direct result of the nature of the ligand bound. Interestingly, many in vivo models of T cell activation are compatible with a selective signaling model, and several studies have shown that peptide analogs can play a role in various T cell biologic phenomena. These data strongly suggest that naturally occurring altered peptide ligands for any TCR exist in the repertoire of self-peptides or, in nature, derived from pathogens, and recent reports provide compelling evidence that this is indeed the case. The concept of altered peptide ligands, their effects on T cell signaling, the hypothesized mechanisms by which they exert their effects, and their possible roles in shaping the T cell immune response are the scope of this review.

Citing Articles

Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer.

Talpin A, Maia A, Carpier J, Kulakowski G, Aubergeon L, Kervevan J J Immunother Cancer. 2025; 13(2).

PMID: 39979071 PMC: 11842988. DOI: 10.1136/jitc-2024-010192.


Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders.

Song Y, Li J, Wu Y Signal Transduct Target Ther. 2024; 9(1):263.

PMID: 39362875 PMC: 11452214. DOI: 10.1038/s41392-024-01952-8.


Molecular insights into metabolite antigen recognition by mucosal-associated invariant T cells.

Awad W, Ciacchi L, McCluskey J, Fairlie D, Rossjohn J Curr Opin Immunol. 2023; 83:102351.

PMID: 37276819 PMC: 11056607. DOI: 10.1016/j.coi.2023.102351.


Influence on Accumulation Levels and Subcellular Localization of Prolamins by Fusion with the Functional Peptide in Transgenic Rice Seeds.

Takaiwa F Mol Biotechnol. 2023; 65(11):1869-1886.

PMID: 36856922 DOI: 10.1007/s12033-023-00666-6.


Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population.

Frasca L, Ocone G, Palazzo R Pathogens. 2023; 12(2).

PMID: 36839505 PMC: 9964607. DOI: 10.3390/pathogens12020233.